![]() |
![]() |
J Acupunct Res > Volume 37(4); 2020 > Article |
|
Study | Sample size (n) | Acupoints | Groups | Duration | Outcome assessment | |
---|---|---|---|---|---|---|
Treatment intervention | Control | |||||
Ou 1999 [18] | 30 (16/14) |
EA) BL23, EX-HN1, GV20 AT) CV4, LR3, SP36, ST36 |
EA | WM (Nimodipine Tab. 20–40 mg, 3×d) | 8 wk | ADL, Effective rate |
Li 2002 [19] | 104 (35/37/18/14) |
EA) BL23, EX-HN1, GB20, GV20 AT) BL17, LR3, PC6, SP10, SP36, ST40 |
EA +HM (Dangguijagyak Powder, Alismatis Rhizoma 10 g, Paeoniae Radix 9 g, Atractylodis Rhizoma Alba 9 g, Poria Sclerotium 9 g, Angelicae Gigantis Radix 6 g, Cnidii Rhizoma 6 g, 2×d) |
C1) EA C2) HM (Dangguijagyak Powder, Alismatis Rhizoma 10 g, Paeoniae Radix 9 g, Atractylodis Rhizoma Alba 9 g, Poria Sclerotium 9 g, Angelicae Gigantis Radix 6 g, Cnidii Rhizoma 6 g, 2×d) C3) WM (Nimodipine Tab. 20–40 mg, 3×d) |
8 wk | MMSE, ADL, Effective rate |
Zhao 2007 [20] | 32 (16/16) | GV14, GV20 | AT | WM (Nimodipine Tab. 20–40 mg, 3×d) | 2 mo | Effective rate, MMSE, ADL |
Liu 2008 [21] | 80 (40/40) | EX-HN3, LI20 | AT | WM (Almitrine & Raubasine Tab., 2×d) | 10 wk | MMSE, Effective rate |
Zhang 2009 [22] | 60 (32/28) | HT7, GB39, GV14, GV20, GV26, PC6, SP36 Eye acupuncture) Kidney area, Heart area, Lower energizer area, Upper energizer area |
AT +HM (Rehmanniae Radix Preparat 20 g, Salviae Radix 15 g, Cnidii Rhizoma 10 g, Angelicae gigantis Radix 10 g, Polygalali Radix 10 g, Ziziphi Spinosae Semen 10 g, Glycyrrhizae Radix 10 g decoction, 2×d) |
HM (Rehmanniae Radix Preparat 20 g, Salviae Radix 15 g, Cnidii Rhizoma 10 g, Angelicae gigantis Radix 10 g, Polygalali Radix 10 g, Ziziphi Spinosae Semen 10 g, Glycyrrhizae Radix 10 g decoction, 2×d) | 180 d | Effective rate |
Zhu 2010 [23] | 80 (20/20/20/20) | BL17, BL23, GV20, SP10 |
AT +HM (Ikjigeonnoe granules, 3×d) |
C1) HM (Ikjigeonnoe granules, 3×d) C2) AT C3) WM (Donepezil Tab. 5 mg, 1×d) |
8 wk | Effective rate, MMSE |
Yin 2013 [24] | 60 (30/30) | MS6 (GV21-GB6), MS7 (GV20-GB7) |
SAT +WM (Donepezil Tab. 5 mg, 1×d) |
WM (Donepezil Tab. 5 mg, 1×d) | 12 wk | MMSE, ADL |
Ke 2014 [25] | 64 (32/32) | CV6, EX-HN1, EX-HN3, GB39, GV20, SP10, ST36 | AT | WM (Donepezil Tab. 5 mg, 1×d) | 4 wk | MMSE, ADL, Effective rate |
Gu 2014 [26] | 141 (72/69) | BL44, GV20, GB20, GB12, CV17, CV12, CV6, SP10, ST36, HT5, SP36, KI3, SP9, ST25, ST40, LR3 | AT | WM (Donepezil Tab. 5 mg, 1×d, after 4 wk increases 10 mg) | 16 wk | MMSE, ADL, ADAS-cog |
Li 2014a [27] | 60 (30/30) | GV20, GV14, BL11, BL13, BL15, BL18, BL20, BL23, CV12, ST25, CV4, ST36, ST39, GB39, KI3, LR3, SP36, LR3, ST40, SP10 |
AT +WM (Donepezil Tab. 5 mg, 1×d) |
WM (Donepezil Tab. 5 mg, 1×d) | 8 wk | Effective rate, MMSE, ADL, ADAS-cog |
Li 2014b [28] | 40 (20/20) | Parietal area, Front parietal area, Forehead area |
SAT +WM (Donepezil Tab. 5 mg, 1×d) |
WM (Donepezil Tab. 5 mg, 1×d) | 8 wk | MMSE, ADL |
Lin 2014 [29] | 36 (18/18) |
EA) PC6, SP6 AT) GV20, EX-HN1 |
EA | WM (Donepezil Tab. 5 mg, 1×d) | 12 wk | MMSE, ADAS-cog, ADL |
Yang 2014 [30] | 60 (30/30) | GV20, EX-HN1, EX-HN3, GB39, BL20, BL23, KI3, ST36 | AT | WM (Donepezil Tab. 5 mg, 1×d) | 4 wk | MMSE, ADL, Effective rate |
Yan 2014 [31] | 40 (20/20) | GV24, GB13, LI4 EX-HN1, HT7, KI3, PC6, EX-HN3, LR3, PC5, CV17, CV23, KI6, ST36, GB34, CV6, CV4, SP9, TE17, SI19, GB20, BL10, GB8, ST25 | AT | WM (Donepezil Tab. 5 mg, 1×d) | 12 wk | MMSE |
Ni 2014 [32] | 60 (30/30) | GV20, EX-HN1, EX-HN3, GB39, HT7, HT9, LR2, LR3 | AT | WM (Donepezil Tab. 5 mg, 1×d) | 4 wk | MMSE, ADL, Effective rate |
Wang 2014 [33] | 55 (27/28) | Coronal suture, Sagittal suture, Lambdoidal suture, Frontotemporal suture, Front frontotemporal suture, Upper frontotemporal suture, Back frontotemporal suture |
SAT +WM (Donepezil Tab. 5–10mg once a day) |
WM (Donepezil Tab. 5–10 mg, 1×d) | 20 d | MMSE, ADAS-cog, Effective rate |
Zhang 2014 [34] | 60 (30/30) | GV20, EX-HN1, EX-HN3, GB39, ST36, CV12, ST40 | AT | WM (Donepezil Tab. 5 mg, 1×d) | 4 wk | MMSE, ADL, Effective rate |
Liao 2015 [35] | 100 (50/50) | MS1, MS5, MS10, MS11 | SAT | HM (Ginkgonis Semen extract) | 3 mo | MMSE, Effective rate |
Liu 2015 [36] | 80 (20/20/20/20) | GV20, GV14 |
AT +HM (Persicae Semen 12 g, Rhei Radix et Rhizoma 9 g, Hirudo 6 g, Tabanus 6 g, Codonopsis Pilosulae Radix 12 g, Astragali Radix 24 g, Poria Sclerotium 18 g, Angelicae Gigantis Radix 12 g, Glycyrrhizae Radix et Rhizoma 6 g decogtion, 1×d) |
C1) HM (Persicae Semen 12 g, Rhei Radix et Rhizoma 9 g, Hirudo 6 g, Tabanus 6 g, Codonopsis Pilosulae Radix 12 g, Astragali Radix 24 g, Poria Sclerotium 18 g, Angelicae Gigantis Radix 12 g, Glycyrrhizae Radix et Rhizoma 6 g decogtion, 1×d) C2) AT C3) WM (Donepezil Tab. 5 mg, 1×d) |
12 wk | Effective rate |
Wang 2015 [37] | 72 (36/36) | EA) GV20, GV14 | EA | WM (Donepezil Tab. 5 mg, 1×d, after 4 wk increases 10 mg) | 12 wk | Effective rate, MMSE |
Bi 2016 [38] | 74 (37/37) | EA) ST36, ST40 | EA | WM (Donepezil Tab. 5 mg, 1×d, after 4 wk increases 10 mg) | 12 wk | MMSE, Effective rate |
Jia 2017 [39] | 79 (40/39) | CV17, CV12, CV6, ST36, TE5, SP10, LR3, GB39, ST40, BL17, ST44, ST25, CV4 | AT | WM (Donepezil Tab. 5 mg, 1×d, after 4 wk increases 10 mg) | 12 wk | ADAS-cog, NPI |
Peng 2017 [40] | 50 (25/25) | EA) GV24, GV20, GV14, GV16, KI1 AT) GV4 | EA | WM (Huperzine A cap. 0.2 mg, 1×d) | 30 d | MMSE, Effective rate |
Li 2018 [41] | 86 (43/43) | EA) GV20, GV14, GV24, GV16 |
EA +HM (Bokbangdansampyeon, Salviae Miltiorrhizae Radix, Notoginseng Radix et Rhizoma, Borneolum, 3×d) |
HM (Bokbangdansampyeon, Salviae Miltiorrhizae Radix, Notoginseng Radix et Rhizoma, Borneolum, 3×d) | 12 wk | MMSE, ADL, Effective rate |
Sun 2018 [42] | 110 (55/55) | GV20, KI1 |
AT +WM (placebo, 2 caps, 2×d) |
WM (placebo, 2 caps, 2×d) | 6 wk | MMSE |
Wang 2018 [43] | 60 (30/30) | CV17, CV12, SP10, CV6, ST36, TE5, GV20, EX-HN1 |
AT +WM (Donepezil Tab. 5 mg, 1×d, increases 10 mg) |
WM (Donepezil Tab. 5 mg, 1×d, increases 10 mg) | 18 wk | MMSE, ADL, ADAS-cog |
Chen 2018 [44] | 96 (48/48) | GV20, GV26, PC6, SP6, GB39, ST40, KI3 |
AT +WM (Donepezil Tab. 5 mg, 1×d) |
WM (Donepezil Tab. 5 mg, 1×d) | 3 mo | Effective rate, ADL, MMSE |
He 2018 [45] | 60 (30/30) |
WAT) GV20, GV14, GV9, GV4 AT) BL23, GB39, KI3 |
WAT +WM (Donepezil Tab. 5 mg, 1×d) |
WM (Donepezil Tab. 5 mg, 1×d) | 12 wk | MMSE, Effective rate |
Feng 2019 [46] | 33 (17/16) |
EA) GV20, GV24, EX-HN5 AT) EX-HN3, GV16, KI4 |
EA | WM (Donepezil Tab. 5 mg, 1×d) | 12 wk | MMSE |
Zhang 2019 [47] | 92 (46/46) | FAT) BL23, BL20, GV20, BL15, ST36, EX-HN1 |
FAT +WM (Donepezil Tab. 5 mg, 1×d, after 4 wk increases 10 mg) |
WM (Donepezil Tab. 5 mg, 1×d, after 4 wk increases 10 mg) | 3 mo | MMSE, ADL, Effective rate |
Wang 2020 [48] | 61 (31/30) |
EA) GB15, GB8 AT) GV20, EX-HN3, GB20, LI4, LI11, ST36, LR3 |
EA +WM (Donepezil Tab. 5 mg, 1×d) |
WM (Donepezil Tab. 5 mg, 1×d) | 8 wk | Effective rate, MMSE, ADAS-cog |
Xia 2020 [49] | 60 (30/30) | EA) GV20, GV16 |
EA +WM (Donepezil Tab. 5 mg, 1×d, after 4 wk increases 10 mg) |
WM (Donepezil Tab. 5 mg, 1×d, after 4 wk increases 10 mg) | 8 wk | ADAS-cog |
E, experimental group; C, control group; EA, electroacupuncture; WM, Western medicine; ADL, Activities of Daily Living; HM, Herbal medicine; MMSE, Mini-Mental State Examination; AT, manual acupuncture; SAT, scalp acupuncture; ADAS-cog, The Alzheimer’s Disease Assessment Scale-Cognitive Subscale; NPI, Dementia NeuroPsychiatric Inventory; WAT, warm acupuncture; FAT, fire acupuncture.
![]() |
![]() |